CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts.

By Christophe Ginestier, Suling Liu, Mark E. Diebel, H. Korkaya, Ming Luo, Marty Brown, Julien Wicinski, O. Cabaud, E. Charafe-Jauffret, D. Birnbaum and 3 more. Journal of Clinical Investigation, 2010

751 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/00018721fbfa6ac28c885387d91f50b8b1bb6a42

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. Aleix Prat
2. G. Lindeman
3. Charles M. Perou
4. Jane E. Visvader
5. Y. Lee
6. M. Wicha

In Molecular Biology

1. Jane E. Visvader
2. M. Wicha
3. Charles M. Perou
4. Y. Lee
5. J. Slingerland
6. R. Taichman
7. G. Dontu

In Oncology

1. Jane E. Visvader
2. M. Wicha
3. H. Korkaya
4. Suling Liu
5. Aleix Prat
6. G. Dontu
7. G. Lindeman
8. Charles M. Perou

Citations in the corpus

• Cancer stem cells: current status and evolving complexities. (2012, background): “Repertaxin-mediated inhibition of this pathway reduced breast tumorigenesis and metastasis but only in combination with chemotherapy (Ginestier et al., 2010).”
• Deconstructing the molecular portraits of breast cancer (2010, methodology): “Blockade of the IL-8 receptor CXCR1 using a CXCR1-specific blocking antibody or repertaxin (a small-molecule CXCR1 inhibitor), selectively depletes the CSC population of the Claudin-low cell line SUM159 (Ginestier et al., 2010).”
• Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases (2017, positive): “Reparaxin also retarded tumor growth and metastasis in xenograft studies [292, 293].”
• Obesity and adverse breast cancer risk and outcome: mechanistic insights and strategies for intervention (2017, background): “IL-8 increased ALDH1 activity and mammosphere and breast cancer xenograft formation, and IL-8 blockade improved response to chemotherapy in mouse models.(143) IL-6,(144) CCL2,(145) and CCL5(146) have all been shown to stimulate CSCs.”
• Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks (2011, background): “We have previously shown that IL8 interacts with the CXCR1 receptor on CSCs, triggering their self-renewal and invasive properties (14, 30).”
• Cancer Stem Cells (CSCs) in Drug Resistance and their Therapeutic Implications in Cancer Treatment (2018, background): “These include CSC markers (ALDH [203], CD44 [204, 205], CD133 [206], EpCAM [207], and HER2 [208]), CSC niche interaction (TAM [209]), tumor microenvironment (immune cells/myeloidderived suppressor cells), cytokines (IL1 [210], IL6 [211], and IL8 [212]), and immune checkpoint (CTLA-4 [213] or PD1/PDL”
• International Union of Basic and Clinical Pharmacology. LXXXIX. Update on the Extended Family of Chemokine Receptors and Introducing a New Nomenclature for Atypical Chemokine Receptors (2014, neutral): “In addition, a recent report suggests that it may have some utility in certain forms of breast cancer (Ginestier et al., 2010).”